Zhonghua nei ke za zhi · 1999
[The serum bactericidal activity of domestic fleroxacin and lomefloxacin].
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao M, Jiang S, Wang R
Аннотация
OBJECTIVE: To evaluate antibacterial activities in vivo and in vitro of fleroxacin and lomefloxacin.
METHODS: Minimal inhibitory concentration (MIC) and serum bactericidal activity (SBA) domestic fleroxacin and lomefloxacin were determined by agar disk dilution method and microplate method respectively. A clinical observation of fleroxacin and lomefloxacin for treating acute bacillary dysentery was carried out.
RESULTS: MIC(90) of fleroxacin against E. coli, K. pneumoniae, S. dysenteriae, S. aureus was 0.25-2 mg/L, being the same as that of ofloxacin. However, MIC(90) of lomefloxacin against the above mentioned species was twice or fourfold as that of ofloxacin and fleroxacin. The percent age of peak SBA > or = 1:8 with ofloxacin, fleroxacin and lomefloxacin against E. coli, K. pneumoniae, S. dysenteriae was 80%-100%, 90%-100% and 50%-80% respectively (P < 0.01). The clinical cure rates of acute bacillary dysentery were 93.3%, 100% and 100% and the bacterial clearance rates were 93.3%, 100% and 100% in the lomefloxacin, fleroxacin and ofloxacin group respectively.
CONCLUSION: The antibacterial activity in vivo and in vitro of fleroxacin against E. coli, K. pneumoniae, S. dysenteriae was similar to that of ofloxacin and stronger than that of lomefloxacin.
METHODS: Minimal inhibitory concentration (MIC) and serum bactericidal activity (SBA) domestic fleroxacin and lomefloxacin were determined by agar disk dilution method and microplate method respectively. A clinical observation of fleroxacin and lomefloxacin for treating acute bacillary dysentery was carried out.
RESULTS: MIC(90) of fleroxacin against E. coli, K. pneumoniae, S. dysenteriae, S. aureus was 0.25-2 mg/L, being the same as that of ofloxacin. However, MIC(90) of lomefloxacin against the above mentioned species was twice or fourfold as that of ofloxacin and fleroxacin. The percent age of peak SBA > or = 1:8 with ofloxacin, fleroxacin and lomefloxacin against E. coli, K. pneumoniae, S. dysenteriae was 80%-100%, 90%-100% and 50%-80% respectively (P < 0.01). The clinical cure rates of acute bacillary dysentery were 93.3%, 100% and 100% and the bacterial clearance rates were 93.3%, 100% and 100% in the lomefloxacin, fleroxacin and ofloxacin group respectively.
CONCLUSION: The antibacterial activity in vivo and in vitro of fleroxacin against E. coli, K. pneumoniae, S. dysenteriae was similar to that of ofloxacin and stronger than that of lomefloxacin.